At the end of June 2012 Flynn Pharma ceased the marketing of Depodur after 3 successful years. Depodur was the only Extended-Release Epidural Opioid for Post-Operative Pain, in the UK. It was distributed through Flynn’s specialist hospital division.
The situation was not brought about by any issues or considerations of safety. To the contrary, user experience in both patient and healthcare professional terms was overwhelmingly positive. Depodur has provided an option in postoperative analgesia that is superior in both efficacy and safety to current standards of care. Nor is the situation a result of a commercial decision on the part of Flynn Pharma. Although the usage in volume terms (numbers of hospitals and usage per hospital) was modest, it had been growing and increasing numbers of hospitals were at advanced stages of formulary approval and the necessary training arrangements to facilitate Depodur’s introduction in their practice.
However, the ‘decision’ was effectively imposed upon Flynn Pharma as a result of the manufacturing partner being unable to continue to make further supplies. For some time Flynn Pharma had been exploring all alternative options including the transfer of production to a new source of supply, but unfortunately none of these efforts proved successful. Flynn Pharma finally had to concede defeat in this matter.
For the users of Depodur, Flynn Pharma continued to supply from existing stock without charge and assisted as far as possible. Flynn Pharma once again would like to offer its sincerest apologies for any inconvenience caused regarding this matter.